Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;63(5):702-708.
doi: 10.1111/ajo.13694. Epub 2023 May 31.

Safety and feasibility of hyperthermic intraperitoneal chemotherapy during interval cytoreductive surgery in patients with advanced high-grade serous ovarian, fallopian tube, peritoneal cancer in an Australian context

Arthur Samoylovich  1 , Bronwyn Jennings  2 , Catherine Shannon  3 , Jermaine I Coward  4 , Rohan Lourie  5 , John Riordan  6 , Nai An Lai  7 , Willemien J van Driel  8 , Nimithri Cabraal  2 , Nisha Jagasia  2 , Naven Chetty  2 , Sanjeev Naidu  9 , Lewis C Perrin  2   10 , Sinead C Barry  2   10
Affiliations

Safety and feasibility of hyperthermic intraperitoneal chemotherapy during interval cytoreductive surgery in patients with advanced high-grade serous ovarian, fallopian tube, peritoneal cancer in an Australian context

Arthur Samoylovich et al. Aust N Z J Obstet Gynaecol. 2023 Oct.

Abstract

Aims: To assess the safety and feasibility of hyperthermic intraperitoneal chemotherapy (HIPEC) during cytoreduction surgery (CRS) in advanced high-grade serous ovarian, fallopian tube and peritoneal cancer within an Australian context.

Methods: Data were collected from 25 consecutive patients undergoing CRS and HIPEC from December 2018 to July 2022 at the Peritoneal Malignancy Service at the Mater Hospital Brisbane, Australia. Data collected included demographics, clinical variables, surgical procedures and complications and intra-operative and post-operative indexes of morbidity.

Results: Twenty-five women who underwent CRS and HIPEC from December 2018 to July 2022 were included in analysis. Findings indicate that CRS with HIPEC is associated with low morbidity.

Conclusion: While judicious patient selection is imperative, HIPEC during CRS was well tolerated by all patients and morbidity was comparable to results from the previously reported OVHIPEC-1 trial. HIPEC appears to be a safe and feasible addition to CRS for the treatment of advanced ovarian cancer in Australian practice.

Keywords: cytoreductive surgery; hyperthermic intraperitoneal chemotherapy (HIPEC); ovarian cancer.

PubMed Disclaimer

References

    1. Australian Institute of Health and Welfare 2021. Cancer in Australia 2021. Cancer Series No. 056. Cat. No. CAN 144. Canberra: AIHW.
    1. Torre LA, Trabert B, DeSantis CE et al. Ovarian cancer statistics, 2018. CA Cancer J Clin 2018; 68: 284-296.
    1. Zhang J, Mei L, Wang F, Li Y. Ten years' disease-free survival of advanced epithelial ovarian cancer treated by cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: A case report and literature review. Medicine (Baltimore) 2020; 99: e23404.
    1. Anuradha S, Webb PM, Jordan SJ et al. Survival of Australian women with invasive epithelial ovarian cancer: A population-based study. Med J Aust 2014; 201(5): 283-288. https://doi.org/10.5694/mja14.00132.
    1. Goodman MD, McPartland S, Detelich D, Saif MW. Chemotherapy for intraperitoneal use: A review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy. J Gastrointest Oncol 2016; 7(1): 45-57. https://doi.org/10.3978/j.issn.2078-6891.2015.111.

LinkOut - more resources